CASI Pharmaceuticals (CASIF) Income towards Parent Company (2022 - 2025)

CASI Pharmaceuticals (CASIF) has 4 years of Income towards Parent Company data on file, last reported at -$77.5 million in Q4 2025.

• Quarterly Income towards Parent Company fell 495.74% year-over-year to -$77.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$109.6 million (down 178.77% YoY) and the FY2025 annual result came in at -$8.6 million, up 77.82% from the prior year.
• Income towards Parent Company retreated to -$77.5 million in Q4 2025, from -$10.7 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$5.1 million in Q3 2023 to a low of -$100.5 million in Q4 2022.
• A 4-year average of -$22.2 million and a median of -$9.3 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company jumped 79.88% — and 2025, when it slumped 495.74%.
• Tracing CASIF's Income towards Parent Company over 4 years: stood at -$100.5 million in 2022, then soared by 35.6% to -$64.7 million in 2023, then soared by 79.88% to -$13.0 million in 2024, then tumbled by 495.74% to -$77.5 million in 2025.
• The last three Income towards Parent Company figures came in at -$77.5 million (Q4 2025), -$10.7 million (Q3 2025), and -$11.1 million (Q2 2025), per Business Quant data.